Physician profile
Ethan E Zimmerman
NPI 1972682292
$3,234.74
in general payments reported to CMS, 2019-2025
26 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $341 · 2021: $172 · 2022: $623 · 2023: $484 · 2024: $405 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $714.35 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $530.83 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $402.53 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $229.52 | 2019-2025 | Arexvy, Shingrix |
| Pfizer INC. | $215.99 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.64 | 2021-2023 | |
| Amgen INC. | $163.27 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $132.51 | 2022-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $109.73 | 2019-2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $65.37 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $63.11 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.87 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.51 | 2019-2022 | |
| Dexcom, INC. | $47.09 | 2021-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $41.06 | 2022-2023 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $36.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.04 | 2025 | Xifaxan |
| Inspire Medical Systems, INC. | $23.30 | 2025 | Inspire |
| Abbott Laboratories | $22.72 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.27 | 2025 | Gvoke Hypopen |
| Janssen Biotech, INC. | $19.44 | 2025 | Stelara, Simponi, Tremfya |
| Phathom Pharmaceuticals, INC. | $18.41 | 2024 | Voquezna |
| Boston Scientific Corporation | $15.45 | 2025 | Bodyguardian |
| Esperion Therapeutics, INC. | $12.62 | 2021 | |
| Allergan, INC. | $12.52 | 2020 | |
| Amarin Pharma, INC. | $12.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Zimmerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.